Tirzepatide: Price, Dosage and Side Effects (Mounjaro, Zepbound)

With commercial insurance that covers Zepbound or Mounjaro, Lilly's savings cards can bring a fill to $25. On Medicare, the GLP-1 Bridge charges $50 a month for the Zepbound KwikPen to people who qualify. Without coverage, the lowest prices I found on 3 October 2026 were Lilly's Zepbound self-pay vials and KwikPens: $299 a month at 2.5 mg, $399 at 5 mg and $449 at higher doses with on-time refills.

You need commercial insurance that covers Zepbound's single-dose pen or Mounjaro, a prescription for an approved use, and Lilly's savings card. The $25 applies to a 1-, 2- or 3-month fill, and the savings are capped: $100 a month and $1,300 a year for Zepbound, $150 a month and $1,950 a year for Mounjaro. The card excludes Medicare, Medicaid and other government programs, and ends on 31 December 2026.

At Lilly's Zepbound self-pay prices on 3 October 2026, the first three 28-day fills on the label's fastest schedule (2.5, 5 and 7.5 mg) cost $299, $399 and $449: $1,147 in total. Three months at 7.5 to 15 mg, refilled on time, cost $1,347. Three months of Mounjaro at the $499 self-pay price cost $1,497. With a covering commercial plan, Lilly's card can bring a 3-month fill to $25.

Not as an approved medicine. Zepbound and Mounjaro are prescription-only, and Lilly's self-pay prices also require a prescription. Tirzepatide sold without one, often labelled for research, is not the approved product. FDA says unapproved GLP-1 drugs are not reviewed for safety, effectiveness or quality, and it has documented dosing errors and counterfeits in that supply.

I found no FDA-approved generic. On 3 October 2026, FDA's Drugs@FDA data listed only Eli Lilly's two tirzepatide applications, for Mounjaro and Zepbound. Compounded or "research" tirzepatide is not a generic and has not been through FDA review.

Four uses across two brands. Mounjaro is approved for blood-sugar control in type 2 diabetes and for reducing cardiovascular risk in adults with type 2 diabetes at high cardiovascular risk. Zepbound is approved for chronic weight management and for moderate-to-severe obstructive sleep apnoea in adults with obesity.

Tirzepatide activates two receptors, GIP and GLP-1, where semaglutide activates GLP-1 alone. Both are once-weekly injections with a boxed warning for thyroid C-cell tumours and similar gut side effects. But they are different molecules, with different approved products and different trial data behind each approval.

The label states tirzepatide causes thyroid C-cell tumours in rats, and that whether this occurs in humans is unknown. It is contraindicated in anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.

The approved schedule starts at 2.5 mg once weekly for four weeks, then rises in 2.5 mg steps roughly every four weeks as needed, up to 15 mg once weekly. A prescriber manages the steps against tolerability and response.

No. As with semaglutide, FDA has documented dosing errors, counterfeit product and fraudulent labelling in the compounded and grey-market tirzepatide supply. It has received hundreds of adverse event reports tied to compounded tirzepatide specifically.

The label gives no timeline for a set number of pounds. In the 72-week Zepbound trials, average weight loss was 15% at 5 mg, 19.5% at 10 mg and 20.9% at 15 mg, against 3.1% on placebo. It built up gradually through the dose steps and maintenance, not in an early burst. When one person reaches 20 lb depends on starting weight, dose and individual response.

The main ones are gut side effects (nausea, diarrhoea, vomiting and constipation), most common during dose increases. There is also a boxed warning for thyroid C-cell tumours and a weekly injection with a months-long titration under a prescriber. It slows stomach emptying, which can affect how other oral medicines and oral contraceptives are absorbed.

The label doesn't describe a mood effect, and no trial behind it measured wellbeing. Tirzepatide does slow stomach emptying, reduce appetite and steady blood sugar, so losing the hunger, cravings or glucose swings that used to disrupt someone's day can feel like a big change. That is a plausible explanation, not a documented drug effect.

It must not be used by anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, or a known serious allergy to tirzepatide or its ingredients. The label also carries precautions for a history of pancreatitis, gallbladder disease or diabetic retinopathy, and says to stop once pregnancy is recognised. Whether any of that applies to you is a question for the prescriber.

Gut reactions are by far the most common. At the 15 mg maintenance dose, the Zepbound label reports nausea in 28% of patients, diarrhoea in 23%, vomiting in 13% and constipation in 11%, plus injection-site reactions in about 8%. The boxed warning covers thyroid C-cell tumours seen in rats. The label also lists pancreatitis, gallbladder disease, low blood sugar with certain diabetes medicines, and kidney injury tied to dehydration.

Per the label: don't raise the dose sooner than four weeks on the current one, and don't rely on oral contraceptives alone for four weeks after starting and after each increase. Don't let vomiting or diarrhoea leave you dehydrated, which is tied to kidney injury, and stop once pregnancy is recognised. A compounded or research vial is not the approved product, and FDA has documented dosing errors and counterfeits in that supply.

Tirzepatide is sold under the brand names Mounjaro and Zepbound, made by Eli Lilly. Mounjaro is approved for type 2 diabetes: improving blood-sugar control alongside diet and exercise in adults and children 10 years and older, and lowering the risk of major cardiovascular events in adults at high risk. Zepbound is approved for chronic weight management in adults with obesity or overweight with at least one weight-related condition, and moderate-to-severe obstructive sleep apnea in adults with obesity.

The generic name for Mounjaro is tirzepatide. Mounjaro is Eli Lilly's brand, approved for type 2 diabetes: improving blood-sugar control alongside diet and exercise in adults and children 10 years and older, and lowering the risk of major cardiovascular events in adults at high risk.

The generic name for Zepbound is tirzepatide. Zepbound is Eli Lilly's brand, approved for chronic weight management in adults with obesity or overweight with at least one weight-related condition, and moderate-to-severe obstructive sleep apnea in adults with obesity.

Yes. Mounjaro is a brand of tirzepatide, made by Eli Lilly: the active ingredient is tirzepatide. It comes as a once-weekly injection (single-dose pen or vial, 4-dose multi-dose vial, or 4-dose KwikPen), dosed at 2.5 mg once weekly to start, up to 15 mg once weekly in adults (10 mg in children). Compounded or research-vial tirzepatide is not Mounjaro and has not been through its FDA review.

Yes. Zepbound is a brand of tirzepatide, made by Eli Lilly: the active ingredient is tirzepatide. It comes as a once-weekly injection (single-dose pen or vial, 4-dose multi-dose vial, or 4-dose KwikPen), dosed at 2.5 mg once weekly to start, maintenance 5, 10 or 15 mg, up to 15 mg once weekly. Compounded or research-vial tirzepatide is not Zepbound and has not been through its FDA review.

Mounjaro and Zepbound contain the same active ingredient, tirzepatide, and both are made by Eli Lilly. They are approved for different uses and doses: Mounjaro for type 2 diabetes: improving blood-sugar control alongside diet and exercise in adults and children 10 years and older, and lowering the risk of major cardiovascular events in adults at high risk (2.5 mg once weekly to start, up to 15 mg once weekly in adults (10 mg in children)); Zepbound for chronic weight management in adults with obesity or overweight with at least one weight-related condition, and moderate-to-severe obstructive sleep apnea in adults with obesity (2.5 mg once weekly to start, maintenance 5, 10 or 15 mg, up to 15 mg once weekly).